Last10K.com

Navidea Biopharmaceuticals, Inc. (NAVB) SEC Filing 8-K Material Event for the period ending Tuesday, March 16, 2021

SEC Filings

NAVB Valuations

Intrinsic Value
Financial Stability
Financial Ratios
Insider Trades
Manager Portfolios
Notifications

NAVB Annual Reports

NAVB Quarterly Reports

NAVB Corporate News

NAVB Registration of Securities

Navidea Biopharmaceuticals, Inc.

HISTORY TOOLS
CIK: 1691944 Ticker: NAVB

View differences made from one to another to evaluate Navidea Biopharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Navidea Biopharmaceuticals, Inc..

Continue

Assess how Navidea Biopharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Navidea Biopharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools
Ticker: NAVB
CIK: 810509
Form Type: 8-K Corporate News
Accession Number: 0001437749-21-006318
Submitted to the SEC: Wed Mar 17 2021 4:07:04 PM EST
Accepted by the SEC: Wed Mar 17 2021
Period: Tuesday, March 16, 2021
Industry: In Vitro And In Vivo Diagnostic Substances
Events:
  1. Other Events

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/navb/0001437749-21-006318.htm